NCT06542614

Treatment of Moderate to Severe Plaque Psoriasis

A Phase II Clinical Trial to Evaluate the Efficacy, Safety, Pharmacokinetics (PK), and Pharmacodynamic (PD) Profile of TQH3906 in Subjects With Moderate to Severe Plaque Psoriasis

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 209 (actual)
• Sponsor: Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. · Industry
• Sex: All
• Age: 18 Years – 70 Years
• Healthy volunteers: Not accepted

Summary

To assess the efficacy and safety of TQH3906 in subjects with moderate to severe plaque psoriasis, as well as the PK and PD characteristics of multiple doses

Conditions

• Plaque Psoriasis

Interventions

Type	Name	Description
DRUG	TQH3906 capsules	To assess the efficacy and safety of TQH3906 in subjects with moderate to severe plaque psoriasis.
DRUG	Placebo of TQH3906 capsules	Placebo without drug substance.

Timeline

• Start date: 2024-08-27
• Primary completion: 2025-11-03
• Completion: 2025-12-06
• First posted: 2024-08-07
• Last updated: 2026-01-30

Locations

35 sites across 1 country: China